By choosing when to finish recruiting for each monotherapy trial (DEP Cabaz and DEP docetaxel), it will have been easy for them to engineer the finishing of those two trials around the same time.
I am not sure it was Starpharma's 'choosing' or 'engineering' in relation to the cessation of recruitment for these two DEP trials ....
..... the CEO stated at the 2022 AGM that Starpharma was struggling to recruit trial participants for their in house DEP trials as oncologists were opting for newer and improved treatments over the old DEP drugs .... that I think you will find contributed heavily to them deciding to conclude these trials (thankfully or IMO they would still be going) - go back and listen to the AGM tape as it is all there
Optimism, page-39
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.31M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.9¢ | $14.97K | 151.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 372123 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 5042 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| SPL (ASX) Chart |